Report : North America Endocrine Disruption Screening Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Assay Type ( In-Vitro, In-Vivo ), Application ( Natural materials and Synthetic materials ), Sources of waste ( Incineration and landfill, Agricultural runoff, Industrial and municipal effluents, Pulp mill effluents, Consumer products, and Others ), Method ( Estrogen Receptor (ER) Transactivation, Androgen Receptor (AR) Transactivation, Androgen Receptor (AR) Modulation, Estrogen Receptor-alpha (ER-alpha) Binding, Estrogen Receptor-beta (ER-beta) Binding, Androgen Receptor (AR) Binding, Steroidogenesis, Aromatase Assay, and Others ), and End User ( Pharmaceutical and Biopharmaceutical companies, Cosmetics and Household Product companies, Food industry, and Chemical industry )
In-Virto Segment to Dominate North America Endocrine Disruption Screening Market during 2020–2028
According to a new market research study on “North America Endocrine Disruption Screening Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Assay Type, Application, Source of Waste, Method, End-User” is expected to reach US$ 61,319.50 million by 2028 from 50,311.25 US$ million in 2021. The market is estimated to grow at a CAGR of 2.9% from 2021 to 2028. The report provides trends prevailing in the North America endocrine disruption screening market along with the drivers and restraints pertaining to the market growth. Rising prevalence of endocrine disorders is the major factor driving the growth of the North America endocrine disruption screening market. However, issues associated with screening technology being expensive hinders the growth of North America endocrine disruption screening market.
North America endocrine disruption screening market is segmented into assay type, application, source of waste, method, end-user, and country. The North America endocrine disruption screening market, by assay type, is bifurcated into in-vitro and in-vivo. The in-vitro segment led the market in 2021. By application, the North America endocrine disruption screening market is bifurcated into natural materials and synthetic materials. In 2021. The endocrine disruption screening market, by source of waste, is segmented into incineration and landfill, agricultural runoff, industrial and municipal effluents, pulp mill effluents, consumer products, and others. In 2021, the incineration and landfill segment held the largest share of the market. The North America endocrine disruption screening market, by method, is segmented into estrogen receptor (ER) transactivation, androgen receptor (AR) transactivation, androgen receptor (AR) modulation, estrogen receptor-alpha (ER) binding, estrogen receptor beta (ER) binding, androgen receptor (AR) binding, steroidogenesis, aromatase assay, and others. In 2021, the estrogen receptor (ER) transactivation segment held the largest share of the market. The North America endocrine disruption screening market, based on end use, is segmented into pharmaceutical and biopharmaceutical companies, cosmetics and household product companies, food industry, and chemical industry. In 2021, the pharmaceutical and biopharmaceutical companies segment held the largest share of the market. Based on country, the North America endocrine disruption screening market is segmented into US, Canada, and Mexico. US held the largest market share in 2020.
North America is highly affected due to the outbreak of the COVID-19. Countries such as the US and Canada reported the highest numbers of COVID-19 positive cases. The US registered highest number of deaths due to the COVID-19 pandemic. The chaotic situation was created in the various industry across the countries and increased the demand for diagnosis and screening devices. The life sciences segment thrives due to increased demand for in-vitro diagnostic products and rising research and development activities. Chronic diseases are common in patients at high risk of severe forms of COVID-19; however, other risk factors may also play a role. Environmental stresses, including as endocrine disrupting chemicals (EDCs), can aggravate the course of COVID-19 and contribute to the development of some chronic disorders. Several research studies have shown that patients with thyroid issues are more susceptible to the COVID 19 virus. The more severe the COVID-19, the lower the TSH and TT3 levels were, with statistical significance, according to a January 2021 research report titled "Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study." The severity of the condition was positively linked with the degree of declines in TSH and TT3 levels. As a result, alterations in serum TSH and TT3 levels are key symptoms of COVID-19 regimens.
aALPHA ANALYTICAL, Inc.; Charles River Laboratories, Inc.; Creative Bioarray; Eurofins Scientific Ltd.; JRF Global; Mérieux NutriSciences; SGS SA; and Smithers are among the leading companies in the North America endocrine disruption screening market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2021, Alpha Analytical now offers PCB congener analysis by EPA Method 1668A for the reporting of all 209 PCB congeners. They also provide an analysis specific to the WHO dioxin-like congeners. Toxic equivalents (TEQs) are calculated and included in the report.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com